Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06657209 · ClinicalTrials.gov registry record · Phase 4
Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
A Phase 4 study, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 104
- Enrollment target
NCT06657209: Recruiting Phase 4 study, sponsored by Stanford University.
NCT06657209 is a Phase 4 study that is actively recruiting participants, run by Stanford University. The registered enrollment target is 104 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06657209, a Phase 4 study, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 104 participants
- Enrollment target
Study Summary
This study is to investigate how adipocyte (fat cell) function and fat distribution differ between individuals with normal-weight type 2 diabetes (NWD), those with overweight type 2 diabetes (OWD), and normal-weight controls without diabetes (NWC). The study will assess whether adipocyte-directed therapies, specifically pioglitazone and tirzepatide, can improve insulin resistance, adipocyte function, and fat distribution in individuals with NWD. By analyzing the biological mechanisms underlying adipocyte dysfunction, the study aims to provide insights into novel treatment strategies for improving metabolic health in normal-weight individuals with type 2 diabetes.
Primary Outcome
Insulin resistance will be measured by a Steady State Plasma Glucose test (SSPG). Results will be measured by glucose levels at steady state in mg/dL.
Interventions
- PROCEDURE MRI
- PROCEDURE Fat biopsy
- PROCEDURE Insulin resistance testing
- PROCEDURE OGTT
- RADIATION DXA scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2025-01-13 |
| Est. Completion | 2027-12-15 |
| Phase | Phase 4 |
What NCT06657209 shows while recruiting
NCT06657209 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 5 interventions - of which MRI is the first listed.
NCT06657209 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06657209 about?
NCT06657209 is a clinical study titled "Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide". This study is to investigate how adipocyte (fat cell) function and fat distribution differ between individuals with normal-weight type 2 diabetes (NWD), those with overweight type 2 diabetes (OWD), and normal-weight controls without diabetes (NWC). The study will assess whether adipocyte-directed th...
What is the current status of trial NCT06657209?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 104 participants. The study started on 2025-01-13. Estimated completion is 2027-12-15.
What interventions are being tested in trial NCT06657209?
The interventions under investigation include: MRI (PROCEDURE), Fat biopsy (PROCEDURE), Insulin resistance testing (PROCEDURE), OGTT (PROCEDURE), DXA scan (RADIATION).
Who is sponsoring clinical trial NCT06657209?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06657209's enrollment target sits among peer trials
104 754th of 2000 higher than 1,241 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI